What’s New

FDA Grants Revalesio Orphan Drug Status for ALS Investigational Drug RNS60
TACOMA, Wash. – September 20, 2017 – Revalesio announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for the investigational drug RNS60 for the treatment...
Read more
RNS60 Shows Promise as an Inhaled Therapy in a Mouse Model of Multiple Sclerosis
The findings of a collaborative project between researchers at Rush University in Chicago and Revalesio were published in the journal Neurochemical Research. An earlier study by the same group had...
Read more